A Double-Blind Placebo-Controlled Trial of a Pancreatic Enzyme Formulation (Panzytrat® 25 000) in the Treatment of Impaired Lipid Digestion in Patients with Cystic Fibrosis
Drug Investigation, ISSN: 1179-1918, Vol: 5, Issue: 5, Page: 274-280
1993
- 8Citations
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
In 15 children (mean age 12 years) with proven cystic fibrosis and a lipid absorption coefficient (LAC) < 90%, the efficacy of a pancreatic enzyme formulation (Panzytrat® 25 000) was compared with placebo in a randomised double-blind parallel group study. The 14 patients evaluated for efficacy received Panzytrat® 25 000 (n = 7) or placebo (n = 7) orally during meals, in an age-adjusted dosage of 2 (< 18 months), 4 (18 months to puberty) or 6 (postpubertal) capsules daily for 8 days. Baseline values were established after treatment with a conventional powdered pancreatin preparation and an age-adjusted diet. After treatment, the mean LAC was 80.5% in the Panzytrat® 25 000 group compared with 55.6% in the placebo group. In the Panzytrat® 25 000 group there was an improvement in LAC (+25%), stool weight (−46%), and in nondigested (−38%) and nonabsorbed (−47%) faecal fat. In contrast, in the placebo group there was a worsening of all 4 of these parameters with changes of −10% for LAC, +32% for stool weight, +36% for non-digested fat, and +46% for nonabsorbed fat. The difference between the Panzytrat® 25 000 and the placebo groups was statistically significant (p < 0.01) for all 4 parameters. Subjective assessment of efficacy by the clinician was rated as ‘good’ or ‘excellent’ for 86% of patients in the Panzytrat® 25 000 group compared with 14% of those in the placebo group (p = 0.015). Tolerability was ‘good’ or ‘excellent’ in all patients except one placebo recipient who complained of digestive upset. © 1993, Adis International Limited. All rights reserved.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0027311144&origin=inward; http://dx.doi.org/10.1007/bf03259592; http://link.springer.com/10.1007/BF03259592; http://link.springer.com/content/pdf/10.1007/BF03259592; http://link.springer.com/content/pdf/10.1007/BF03259592.pdf; http://link.springer.com/article/10.1007/BF03259592/fulltext.html; http://www.springerlink.com/index/pdf/10.1007/BF03259592; http://www.springerlink.com/index/10.1007/BF03259592; https://dx.doi.org/10.1007/bf03259592; https://link.springer.com/article/10.1007/BF03259592
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know